Alkermes Announces Commercial Availability Of LYBALVI® For The Treatment Of Schizophrenia & Bipolar I Disorder

Alkermes plc announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproate. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity.

LYBALVI® (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the . . .